开云app官网登录入口网页版-官方正版

#抗性#

219篇内容 | 2995人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1666110, encodeId=e296166611035, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, objectType=article, longId=739073, objectId=814ce3907329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=814ce3907329, replyNumber=0, likeNumber=113, createdTime=2022-09-22, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=814ce3907329, moduleTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=814ce3907329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666109, encodeId=bbc8166610940, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, objectType=article, longId=738674, objectId=c94ce38674b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c94ce38674b5, replyNumber=0, likeNumber=104, createdTime=2023-08-05, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c94ce38674b5, moduleTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c94ce38674b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666108, encodeId=307816661082e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=729045, objectId=c007e2904512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c007e2904512, replyNumber=0, likeNumber=136, createdTime=2023-03-06, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c007e2904512, moduleTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c007e2904512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666105, encodeId=43cb16661057e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Br J Cancer：5-氨基酮戊酸增加线粒体活性氧的产生降低前列腺癌的放疗抗性, objectType=article, longId=724005, objectId=bacee2400512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacee2400512, replyNumber=0, likeNumber=105, createdTime=2023-01-09, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacee2400512, moduleTitle=Br J Cancer：5-氨基酮戊酸增加线粒体活性氧的产生降低前列腺癌的放疗抗性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bacee2400512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666100, encodeId=f16d16661009d, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌中，激素治疗与化疗获益的预测性基因组生物标志物调查, objectType=article, longId=220484, objectId=e3c4220484eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3c4220484eb, replyNumber=0, likeNumber=118, createdTime=2022-06-27, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3c4220484eb, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌中，激素治疗与化疗获益的预测性基因组生物标志物调查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e3c4220484eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666103, encodeId=bf6416661031a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=295173, objectId=79422951e301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79422951e301, replyNumber=0, likeNumber=95, createdTime=2022-08-21, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79422951e301, moduleTitle=Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=79422951e301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666097, encodeId=42a4166609e46, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Int J Urol：转移去势抵抗性前列腺癌中，一线治疗生存结果的预测因素调查, objectType=article, longId=218948, objectId=70c9218948f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70c9218948f1, replyNumber=0, likeNumber=82, createdTime=2022-03-20, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70c9218948f1, moduleTitle=Int J Urol：转移去势抵抗性前列腺癌中，一线治疗生存结果的预测因素调查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=70c9218948f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666106, encodeId=ac521666106ca, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur J Cancer：二甲双胍和他汀类药物对转移性去势抵抗性前列腺癌患者预后的影响, objectType=article, longId=727118, objectId=4bc9e2711830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bc9e2711830, replyNumber=0, likeNumber=122, createdTime=2023-02-03, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bc9e2711830, moduleTitle=Eur J Cancer：二甲双胍和他汀类药物对转移性去势抵抗性前列腺癌患者预后的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4bc9e2711830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666093, encodeId=46941666093f5, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=215592, objectId=aefb21559219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefb21559219, replyNumber=0, likeNumber=110, createdTime=2022-06-24, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefb21559219, moduleTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aefb21559219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666104, encodeId=f6d81666104dd, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Clin Cancer Res：瑞博西尼联合多西他赛治疗转移性去势抵抗性前列腺癌, objectType=article, longId=299388, objectId=6e0a29938862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e0a29938862, replyNumber=0, likeNumber=128, createdTime=2022-10-17, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0a29938862, moduleTitle=Clin Cancer Res：瑞博西尼联合多西他赛治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6e0a29938862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666107, encodeId=43fe166610ec1, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点, objectType=article, longId=728547, objectId=db53e28547ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db53e28547ba, replyNumber=0, likeNumber=102, createdTime=2022-08-06, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db53e28547ba, moduleTitle=Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db53e28547ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666096, encodeId=8b4d1666096fb, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur Urol：Avelumab联合SABR是否能促进转移去势抵抗性前列腺癌的疗效？ , objectType=article, longId=217567, objectId=1e9121e567e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9121e567e8, replyNumber=0, likeNumber=111, createdTime=2022-06-21, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9121e567e8, moduleTitle=Eur Urol：Avelumab联合SABR是否能促进转移去势抵抗性前列腺癌的疗效？ , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e9121e567e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666090, encodeId=6e7c16660906e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur Urol：卡巴他赛与阿比特龙或恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的疗效和安全性比较研究 , objectType=article, longId=215282, objectId=daad21528299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daad21528299, replyNumber=0, likeNumber=92, createdTime=2022-02-25, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daad21528299, moduleTitle=Eur Urol：卡巴他赛与阿比特龙或恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的疗效和安全性比较研究 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=daad21528299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666085, encodeId=3f5016660858c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=JAMA Netw Open：化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系, objectType=article, longId=213835, objectId=38ec21383567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38ec21383567, replyNumber=0, likeNumber=94, createdTime=2021-12-31, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38ec21383567, moduleTitle=JAMA Netw Open：化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=38ec21383567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666098, encodeId=b3e916660980d, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Prostate：11C-choline PET/CT在转移去势抗性前列腺癌患者中的预后价值如何？ , objectType=article, longId=219993, objectId=b19721999311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19721999311, replyNumber=0, likeNumber=112, createdTime=2022-02-02, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19721999311, moduleTitle=Prostate：11C-choline PET/CT在转移去势抗性前列腺癌患者中的预后价值如何？ , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b19721999311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666084, encodeId=c4ed1666084f0, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Nat Commun：细胞外基质和适应性粘附动力学共同驱动卵巢癌的化疗抗性, objectType=article, longId=213538, objectId=dc92213538df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc92213538df, replyNumber=0, likeNumber=151, createdTime=2022-01-29, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc92213538df, moduleTitle=Nat Commun：细胞外基质和适应性粘附动力学共同驱动卵巢癌的化疗抗性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dc92213538df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666102, encodeId=8a97166610264, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=益普生直击2020 EAU 周芳坚教授：去势抵抗性前列腺癌新近进展, objectType=article, longId=291931, objectId=c5962919319b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5962919319b, replyNumber=0, likeNumber=84, createdTime=2022-09-14, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5962919319b, moduleTitle=益普生直击2020 EAU 周芳坚教授：去势抵抗性前列腺癌新近进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c5962919319b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666082, encodeId=b9f61666082ea, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=NEJM：177Lu-PSMA-617靶向放疗治疗PSMA阳性转移性去势抵抗性前列腺癌, objectType=article, longId=213197, objectId=2d2e21319ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d2e21319ed9, replyNumber=0, likeNumber=108, createdTime=2021-07-08, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2e21319ed9, moduleTitle=NEJM：177Lu-PSMA-617靶向放疗治疗PSMA阳性转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2d2e21319ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666081, encodeId=a9e616660813d, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Sci Immunol：全反式维甲酸帮助攻克实体瘤的放疗抗性, objectType=article, longId=213044, objectId=9d15213044b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d15213044b5, replyNumber=0, likeNumber=107, createdTime=2022-02-04, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d15213044b5, moduleTitle=Sci Immunol：全反式维甲酸帮助攻克实体瘤的放疗抗性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9d15213044b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666099, encodeId=5e11166609929, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, objectTitle=Eur J Cancer：DNA损伤修复状态对卡巴他赛治疗转移性去势抵抗性前列腺癌的活性的影响, objectType=article, longId=220037, objectId=996422003ee6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996422003ee6, replyNumber=0, likeNumber=118, createdTime=2022-08-10, rootId=0, userName=yige2012, userId=4d5926034382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996422003ee6, moduleTitle=Eur J Cancer：DNA损伤修复状态对卡巴他赛治疗转移性去势抵抗性前列腺癌的活性的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=996422003ee6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

抗性

2020-05-29

yige2012 (审核中...)

前往app查看评论内容

#抗性#

ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当

2022-09-22

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后

2023-08-05

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌

2023-03-06

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Br J Cancer：5-氨基酮戊酸增加线粒体活性氧的产生降低前列腺癌的放疗抗性

2023-01-09

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur Urol：转移去势抵抗性前列腺癌中，激素治疗与化疗获益的预测性基因组生物标志物调查

2022-06-27

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性

2022-08-21

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Int J Urol：转移去势抵抗性前列腺癌中，一线治疗生存结果的预测因素调查

2022-03-20

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur J Cancer：二甲双胍和他汀类药物对转移性去势抵抗性前列腺癌患者预后的影响

2023-02-03

hb2008ye (审核中...)

前往app查看评论内容

#抗性#

Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性

2022-06-24

智慧医人 (审核中...)

前往app查看评论内容

#抗性#

Clin Cancer Res：瑞博西尼联合多西他赛治疗转移性去势抵抗性前列腺癌

2022-10-17

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点

2022-08-06

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur Urol：Avelumab联合SABR是否能促进转移去势抵抗性前列腺癌的疗效？

2022-06-21

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur Urol：卡巴他赛与阿比特龙或恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的疗效和安全性比较研究

2022-02-25

yige2012 (审核中...)

前往app查看评论内容

#抗性#

JAMA Netw Open：化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系

2021-12-31

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Prostate：11C-choline PET/CT在转移去势抗性前列腺癌患者中的预后价值如何？

2022-02-02

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Nat Commun：细胞外基质和适应性粘附动力学共同驱动卵巢癌的化疗抗性

2022-01-29

yige2012 (审核中...)

前往app查看评论内容

#抗性#

益普生直击2020 EAU 周芳坚教授：去势抵抗性前列腺癌新近进展

2022-09-14

yige2012 (审核中...)

前往app查看评论内容

#抗性#

NEJM：177Lu-PSMA-617靶向放疗治疗PSMA阳性转移性去势抵抗性前列腺癌

2021-07-08

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Sci Immunol：全反式维甲酸帮助攻克实体瘤的放疗抗性

2022-02-04

yige2012 (审核中...)

前往app查看评论内容

#抗性#

Eur J Cancer：DNA损伤修复状态对卡巴他赛治疗转移性去势抵抗性前列腺癌的活性的影响

2022-08-10

科室
- - 订阅+
  - 更多科室
工具
服务